Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03699995 · ClinicalTrials.gov registry record · NA
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
A NA study of Cutaneous Melanoma and Skin Carcinoma, sponsored by OHSU Knight Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03699995 is a NA study of Cutaneous Melanoma and Skin Carcinoma that is active but no longer recruiting, run by OHSU Knight Cancer Institute. The registered enrollment target is 100 participants, below the 364-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03699995, a NA study of Cutaneous Melanoma and Skin Carcinoma, is active but no longer recruiting, sponsored by OHSU Knight Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well MoleMapper, Visiomed, and confocal microscopy work in screening participants for melanoma. Analyzing images (photographs) made with three different portable imaging systems may be as good as a visit to a dermatologist's office for finding melanomas before they can spread.
Conditions Studied
Interventions
- PROCEDURE Imaging Procedure
- DRUG Lidocaine
- PROCEDURE Punch Biopsy
- OTHER Confocal Microscopy
- OTHER Dermoscopy
Study Locations (1)
Oregon
- Sancy Leachman - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-05-18 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03699995
The ClinicalTrials.gov registry entry for NCT03699995 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 364-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (73% lower). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cutaneous Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Imaging Procedure is the first listed.
NCT03699995 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT03699995 about?
NCT03699995 is a clinical study titled "MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma". This trial studies how well MoleMapper, Visiomed, and confocal microscopy work in screening participants for melanoma. Analyzing images (photographs) made with three different portable imaging systems may be as good as a visit to a dermatologist's office for finding melanomas before they can spread.
What is the current status of trial NCT03699995?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2018-05-18. Estimated completion is 2026-12-31.
What conditions does trial NCT03699995 study?
This clinical trial studies the following conditions: Cutaneous Melanoma, Skin Carcinoma, Melanocytic Nevus.
What interventions are being tested in trial NCT03699995?
The interventions under investigation include: Imaging Procedure (PROCEDURE), Lidocaine (DRUG), Punch Biopsy (PROCEDURE), Confocal Microscopy (OTHER), Dermoscopy (OTHER).
Who is sponsoring clinical trial NCT03699995?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03699995 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
RECRUITING · NA
-
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RECRUITING · Phase 2
-
ACTengine® IMA203 Combined With mRNA-4203
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.